Tim Cortese

The European Commission has approved tislelizumab plus chemotherapy as treatment for patients with esophageal and gastric or GEJ cancer.

Tiragolumab with atezolizumab, when compared with placebo with atezolizumab, failed to reach its overall survival end point in patients with NSCLC.

For patients with KRAS-mutated colorectal cancer, onvansertib plus FOLFIRI/bevacizumab was effective in those who had not received prior bevacizumab.

A BLA has been accepted by the FDA for 2 belantamab mafodotin combinations that have shown positive results in patients with multiple myeloma.

The VIOLETTE trial, which used OBT-fusion technology for patients with focal ablation of the prostate by microwave needles, released interim results.

Vusolimogene oderparepvec in combination with nivolumab has received breakthrough therapy designation from the FDA in advanced melanoma.

Darolutamide with androgen deprivation therapy has shown promising efficacy and safety results for patients with hormone-sensitive prostate cancer.

For patients with NSCLC, subcutaneous pembrolizumab appeared noninferior vs intravenous pembrolizumab for study end points when combined with chemotherapy.

FoundationOne Liquid CDx has been approved as a diagnostic tool for tepotinib in patients with non–small cell lung cancer METex14 skipping alterations.

Pembrolizumab with platinum-based chemotherapy yielded encouraging progression-free and overall survival outcomes in this patient population.

A nurse practitioner gives a closer look into the risk factors, diagnosis, adverse effects, and future treatments associated with pancreatic cancer.

The CHMP recommended for approval nivolumab/ipilimumab for patients with MSI-H and dMMR unresectable or metastatic colorectal cancer.

Patients with any type of cancer showed better QOL after undergoing the radical remission multimodal intervention method.

Barriers and gaps in treatment and care for patients diagnosed with gynecologic cancers were reported in a recent survey.

Denileukin diftitox plus pembrolizumab yields objective responses and clinical benefit in patients with recurrent solid tumors.

Stereotactic body radiotherapy showed noninferior biochemical or clinical failure compared with standard radiotherapy in select patients with prostate cancer.

Camizestrant showed better progression-free survival than fulvestrant across various subgroups of patients with advanced breast cancer.

Early results from the iMMagine-1 trial show anito-cel as a promising therapy in relapsed/refractory multiple myeloma.

Patients who start smoking cessation treatment after cancer diagnosis are found to have higher rates of survival.

The developers of paxalisib will have a Type C meeting with the FDA to discuss its registration as treatment for newly diagnosed glioblastoma.

Disease-free survival and overall survival were lower with extended lymphadenectomy compared with standard lymphadenectomy.

Hematologic cell transplantation use rates have improved, although they still show disparities for minority groups such as non-Hispanic Black populations.

Major clinical trials lack documentation and participation data on Native Hawaiians and Pacific Islanders, a recent study finds.

Ovarian cancer decedents who received early palliative care had improved quality and less aggressive end-of-life care.

Data from the INTERLACE trial shows induction chemotherapy followed by chemoradiotherapy prolongs overall survival in locally advanced cervical cancer.

Inavolisib-based therapy reaches the primary end point of the phase 3 INAVO120 study among patients with PIK3CA-mutated breast cancer.

Patients with anaplastic thyroid cancer had a significant boost to overall survival with atezolizumab and targeted therapy.

Patients with non–small cell lung cancer had a positive long-term benefit with perioperative chemoimmunotherapy, according to the 5-year NADIM trial update.